Table 4. Multivariate analysis.
P -value | Hazard ratio | 95% CI | |
---|---|---|---|
For PFS | |||
Concomitant bisphosphonates vs not | <0.0001 | 3.226 | 1.749–5.950 |
Baseline platelets <400 000 mm−3 vs >400 000 mm−3 | 0.001 | 3.381 | 1.620–7.055 |
Baseline neutrophils >4500 mm−3 vs <4500 mm−3 | 0.027 | 0.512 | 0.284–0.925 |
For OS | |||
Concomitant bisphosphonates vs not | 0.014 | 1.977 | 1.147–3.408 |
Clear cell histology vs other histology | 0.040 | 2.431 | 1.041–5.681 |
Baseline platelets <400 000 mm−3vs >400 000 mm−3 | 0.047 | 2.340 | 1.011–5.415 |
Baseline ECOG PS >0 vs 0 | 0.065 | 0.589 | 0.336–1.034 |
Abbreviations: ECOG PS=Eastern Cooperative Oncology Group performance status; OS=overall survival; PFS=progression-free survival.
The factors that were included for multivariate analysis for PFS were: baseline neutrophil count; baseline platelet count; time from diagnosis metastases to start TKIs; presence of liver metastases; prior nephrectomy vs no prior nephrectomy; sunitinib vs sorafenib; administration of bisphosphonates.
The factors that were included for multivariate analysis for OS were: baseline neutrophil count; baseline platelet count; baseline Eastern Cooperative Oncology Group performance status; presence of liver metastases; prior nephrectomy vs no prior nephrectomy; sunitinib vs sorafenib; clear cell histology vs other histology; administration of bisphosphonates.
Baseline lactate dehydrogenase was not taken into account because few patients presented with elevated values.
Note: On multivariate analysis for PFS, the P-value for the parameter ‘time from diagnosis metastases to start TKIs ⩽6 months or >6 months’ was 0.38. The P-value for the parameter ‘sunitinib vs sorafenib’ was 0.22. On multivariate analysis for OS, the P-value for the parameter ‘sunitinib vs sorafenib’ was 0.51.